$-0.04
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-70 Mln
ROE
-62.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.4
Debt to Equity
0
Book Value
$-1.4
EPS
$-83.8
Face value
--
Shares outstanding
18,982,837
CFO
$-499.56 Mln
EBITDA
$-493.16 Mln
Net Profit
$-593.61 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Evelo Biosciences (EVLO)
| -- | -- | -- | -- | -96.8 | -94.7 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Evelo Biosciences (EVLO)
| -99.8 | -73.5 | -49.8 | 197.8 | -68.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Evelo Biosciences (EVLO)
|
0.0 | 0.0 | 0.0 | -82.4 | -- | -- | -- | 3.5 |
| 73.9 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 65.3 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.9 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 512.4 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 410.5 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.5 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 344.8 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate,... which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read more
President, Secretary, Principal Executive, Financial and Accounting Officer & Director
Mr. Craig R. Jalbert CIRA
President, Secretary, Principal Executive, Financial and Accounting Officer & Director
Mr. Craig R. Jalbert CIRA
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Evelo Biosciences Inc (EVLO) is $0.00 (NASDAQ) as of 24-Apr-2026 09:30 EDT. Evelo Biosciences Inc (EVLO) has given a return of -96.8% in the last 3 years.
Since, TTM earnings of Evelo Biosciences Inc (EVLO) is negative, P/E ratio is not available.
The P/B ratio of Evelo Biosciences Inc (EVLO) is 3.51 times as on 24-Apr-2026, a 23 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.08
|
-1.77
|
|
2021
|
-0.13
|
1.87
|
|
2020
|
-0.30
|
0.93
|
|
2019
|
-0.08
|
0.11
|
|
2018
|
-0.38
|
0.15
|
The 52-week high and low of Evelo Biosciences Inc (EVLO) are Rs 0.00 and Rs 0.00 as of 26-Apr-2026.
Evelo Biosciences Inc (EVLO) has a market capitalisation of $ 0 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Evelo Biosciences Inc (EVLO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.